Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 17 • N.1/2026
OBJECTIVES: The study aimed to analyze the use of intensive lipid-lowering therapy (I-LLT) at discharge in a broad population of patients hospitalized with acute coronary syndrome (ACS).
BACKGROUND: Early and intensive statin therapy in ACS has been shown to reduce cardiovascular morbidity and mortality. Utilization and predictors of I-LLT among hospitalized ACS patients are not known.
METHODS: The GWTG database was analyzed for ACS-related hospitalizations from 2005 to 2009. The use of I-LLT (defined as dose of statin or combination therapy likely to produce > 50% reductions in low-density lipoprotein [LDL]) and less intensive lipid-lowering therapy (LI-LLT) at discharge was assessed. Baseline characteristics and temporal trends in LLT were compared in these 2 treatment groups.
RESULTS: Of 65,396 patients receiving LLT, only 25,036 (38.3%) were treated with an I-LLT regimen. Mean total cholesterol, LDL, and triglycerides were significantly higher in the I-LLT group. Even among those with LDL > 130 mg/dL, 50% or less received I-LLT. Predictors of I-LLT at discharge included LLT before admission, hyperlipidemia, prior coronary artery disease, increasing body mass index, and in-hospital percutaneous coronary intervention. Although there was some temporal improvement in the rate of I-LLT from 2005 to 2007, a decline in use of I-LLT was noted in 2008 and 2009. This was attributed to a sharp reduction in use of ezetimibe in combination with statin, without corresponding increases in intensive statin monotherapy.
CONCLUSIONS: In a large cohort of patients admitted with ACS, most of the eligible patients were not discharged on I-LLT. These data suggest the need for better implementation of guideline-recommended intensive statin therapy in patients with ACS.
40° Congresso NazionaleLazise (VR), 21-23 novembre 2026
Abstract deadline:
7 agosto 2026




Spring Meeting Giovani Ricercatori SID, SIGG, SIIA, SIMI, SIPREC, SISARimini, 19-21 aprile 2026
[continua a leggere]
Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 17 • N.1/2026
Rivista Italiana della
Ipercolesterolemia
Familiare Omozigote
Anno 7 • N.1/2025

Nuovo sito dedicato al Progetto LIPIGEN
Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina
PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina
Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)
E' necessario essere loggati come utente del Gruppo GILA per poter accedere
Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)
Pagina informativa per medici e pazienti